Filgotinib Alone and in Combination With Methotrexate (MTX) in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Are Naive to MTX Therapy
Public ClinicalTrials.gov record NCT02886728. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Placebo- and Active-controlled, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 52 Weeks Alone and in Combination With Methotrexate (MTX) to Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Are Naïve to MTX Therapy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of this study is to evaluate the effects of filgotinib in combination with methotrexate (MTX) versus MTX alone in adults with active rheumatoid arthritis (RA).
Study identification
- NCT ID
- NCT02886728
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,252 participants
Conditions and interventions
Conditions
Interventions
- Filgotinib Drug
- Placebo to match filgotinib Drug
- MTX Drug
- Placebo to match MTX Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 7, 2016
- Primary completion
- Oct 4, 2018
- Completion
- May 7, 2019
- Last update posted
- May 31, 2021
2016 – 2019
United States locations
- U.S. sites
- 45
- U.S. states
- 23
- U.S. cities
- 45
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Huntsville | Alabama | — | — |
| Not listed | Phoenix | Arizona | — | — |
| Not listed | Tucson | Arizona | — | — |
| Not listed | Covina | California | — | — |
| Not listed | Los Angeles | California | — | — |
| Not listed | Palm Desert | California | — | — |
| Not listed | Victorville | California | — | — |
| Not listed | Whittier | California | — | — |
| Not listed | DeBary | Florida | — | — |
| Not listed | Jacksonville | Florida | — | — |
| Not listed | Miami | Florida | — | — |
| Not listed | Orlando | Florida | — | — |
| Not listed | Plantation | Florida | — | — |
| Not listed | Springfield | Illinois | — | — |
| Not listed | Wichita | Kansas | — | — |
| Not listed | Elizabethtown | Kentucky | — | — |
| Not listed | Cumberland | Maryland | — | — |
| Not listed | Wheaton | Maryland | — | — |
| Not listed | Worcester | Massachusetts | — | — |
| Not listed | Saint Clair Shores | Michigan | — | — |
| Not listed | Eagan | Minnesota | — | — |
| Not listed | Hattiesburg | Mississippi | — | — |
| Not listed | Tupelo | Mississippi | — | — |
| Not listed | St Louis | Missouri | — | — |
| Not listed | Lincoln | Nebraska | — | — |
| Not listed | Lebanon | New Hampshire | — | — |
| Not listed | Freehold | New Jersey | — | — |
| Not listed | Toms River | New Jersey | — | — |
| Not listed | Albuquerque | New Mexico | — | — |
| Not listed | Charlotte | North Carolina | — | — |
| Not listed | Oklahoma City | Oklahoma | — | — |
| Not listed | Tulsa | Oklahoma | — | — |
| Not listed | Bethlehem | Pennsylvania | — | — |
| Not listed | Duncansville | Pennsylvania | — | — |
| Not listed | Wyomissing | Pennsylvania | — | — |
| Not listed | Charleston | South Carolina | — | — |
| Not listed | Orangeburg | South Carolina | — | — |
| Not listed | Memphis | Tennessee | — | — |
| Not listed | Beaumont | Texas | — | — |
| Not listed | Carrollton | Texas | — | — |
| Not listed | Corpus Christi | Texas | — | — |
| Not listed | Mesquite | Texas | — | — |
| Not listed | Plano | Texas | — | — |
| Not listed | San Antonio | Texas | — | — |
| Not listed | Webster | Texas | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 141 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02886728, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 31, 2021 · Synced Sep 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02886728 live on ClinicalTrials.gov.